Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US

被引：1
|
作者：
Aguiar, Pedro, Jr. [1 ]
De Mello, Ramon [2 ]
Tadokoro, Hakaru [1 ]
Babiker, Hani [3 ]
Gutierres, Barbara [4 ]
Lopes, Gilberto [5 ]
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Faro, Portugal
[3] Honor Hlth, Scottsdale, AZ USA
[4] Univ Paulista, Sao Paulo, Brazil
[5] Ctr Paulista, Oncol & Oncoclin Grp, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
biomarker; Immunotherapy; Cost of Care; Access;
D O I：
10.1016/j.jtho.2016.11.324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA17.01
引用
收藏
页码：S308 / S308
页数：1
相关论文
共 50 条
  • [21] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [22] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [23] Identifying Resistance to Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in NSCLC
    Leal, T.
    Schehr, J.
    Kaminski, A.
    Campbell, T.
    Traynor, A.
    Lang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S160 - S160
  • [24] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Deborah Blythe Doroshow
    Sheena Bhalla
    Mary Beth Beasley
    Lynette M. Sholl
    Keith M. Kerr
    Sacha Gnjatic
    Ignacio I. Wistuba
    David L. Rimm
    Ming Sound Tsao
    Fred R. Hirsch
    Nature Reviews Clinical Oncology, 2021, 18 : 345 - 362
  • [25] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Doroshow, Deborah Blythe
    Bhalla, Sheena
    Beasley, Mary Beth
    Sholl, Lynette M.
    Kerr, Keith M.
    Gnjatic, Sacha
    Wistuba, Ignacio I.
    Rimm, David L.
    Tsao, Ming Sound
    Hirsch, Fred R.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 345 - 362
  • [26] PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare
    Zouein, Joseph
    Kesrouani, Carole
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2021, 13 (12) : 1053 - 1065
  • [27] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Santoro, Ilka
    Babiker, Hani
    Avancha, Kiran
    Gutierres, Barbara
    Barreto, Carmelia
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
  • [28] PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
    Gray, Steven G.
    Cuffe, Sinead
    Finn, Stephen P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : E142 - E144
  • [29] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [30] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
12345